KLRS
KLRS
NASDAQ · Biotechnology

Kalaris Therapeutics Inc

$4.06
+0.18 (+4.64%)
As of Aug 15, 2:14 AM ET ·
Analyst Consensus
Strong Buy
14
Analysts
Moderate
Coverage
Buy 12 86%
Hold 2 14%
Sell 0 0%
Price Target
Analyst Price Target +463.8% upside
Low Target $19.41
Average Target $22.89
High Target $38.59
Current Price $4.06
Current
$4.06
Target
$22.89
$19.41 $22.89 avg $38.59
Scenario Analysis
Bear Case
$19.41
378.1%
Low target
Base Case
$22.89
+463.8%
Avg target
Bull Case
$38.59
+850.5%
High target
Risk/Reward
2.2x
Favorable
Price in Context
52-Week High
$11.88
-65.8% from high
52-Week Low
$2.14
+89.7% from low
Target vs 52W High
$22.89
+92.7% vs high
Next Earnings Report
Aug 19, 2026
3d
until earnings
EPS Est: $-0.50
Earnings in 3 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 38 82% $257.58 +3.3%
AMGN
Amgen Inc
Hold 43 49% $190.87 -54.0%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +162.1%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 37 81% $438.34 -13.3%
REGN
Regeneron Pharmaceuticals
Buy 37 70% $76.80 -90.4%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -53.9%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -44.0%
BIIB
Biogen Inc
Buy 43 67% $91.45 -56.4%